KRAS and pancreatic intraductal papillary-mucinous neoplasm: Existing diagnostic modalities (CT, MRI, EUS, CEA, and CA19-9 levels; KRAS and GNAS mutations; and cyst fluid cytology) are insufficient for accurately classifying IPMN patients due to their low diagnostic accuracy [15,16,17,18,19,20,21].